Ideaya Biosciences (IDYA) announced that the first patient has been enrolled in its Phase 1 dose escalation/expansion trial evaluating IDE034, an investigational PTK7/B7H3 bispecific TOP1 ADC. The company is planning to evaluate safety, tolerability and PK of IDE034 as a monotherapy in the Phase 1 trial, and also plans to test combinations with agents that target the DNA damage response pathway, such as their proprietary PARG inhibitor, IDE161. Dosing of the first patient with IDE034 triggers a $5M milestone payment from Ideaya to Biocytogen, pursuant to the option and license agreement between the companies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- IDEAYA Biosciences: Methodologically De-Risked OpTimUM-02 Readout and Strong Cash Runway Support Buy Rating
- Ideaya Biosciences appoints Theodora Ross as chief development officer
- IDEAYA Biosciences: Pipeline Progress and Late-Stage Clinical Expansion Support Reiterated Buy Rating
- Ideaya Biosciences price target raised to $65 from $64 at Citi
- Ideaya Biosciences price target raised to $52 from $49 at Wedbush